The President’s Cancer Panel has published an initial assessment of NCI’s National Cancer Plan, offering recommendations in five priority areas to accelerate progress.
To help accelerate research into new treatments for acute myeloid leukemia and myelodysplastic syndrome, Thermo Fisher Scientific Inc. is partnering with NCI on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial.
